John K. Lin

Jun 6, 2024 | jamanetwork.com | Matthew J. Klebanoff |John K. Lin

Adalimumab (Humira) is a top-selling drug in Medicare Part D, representing $4.7 billion of Medicare spending in 2021.1 This anti-inflammatory biologic lost US patent protection in 2023, and a number of manufacturers introduced biosimilar competitors (eTable in Supplement 1). Biosimilars could help lower spending on biologics for Medicare, just as generics have done for small-molecule drugs.

Nov 28, 2023 | healthaffairs.org | John K. Lin |James Barnes |Jalpa A. Doshi |Salah Ghabri |Peter L. Kolominsky-Rabas |Brian O’Rourke

Under the Inflation Reduction Act (IRA) of 2022, the Centers for Medicare and Medicaid Services (CMS) will begin negotiating drug prices for a subset of drugs in Medicare. In doing so, CMS must determine how to price each drug according to its benefits.

Jul 18, 2023 | healthaffairs.org | John K. Lin |James Barnes |Jalpa A. Doshi

The Inflation Reduction Act (IRA) of 2022 tasked the Centers for Medicare and Medicaid Services (CMS) to begin negotiating drug prices with manufacturers for the first time. CMS must consider several factors while negotiating the “lowest maximum fair price.” One factor that has attracted attention is how to fairly price each drug based on its benefits and costs.